Psychosocial Functioning in patients with schizophrenia treated with aripiprazole an office-based real-world setting. results from the German post-marketing surveillance study

Pharmacopsychiatry

Volumn 42, Issue 3, 2009, Pages 101-108

  Bergmann, F ^a   Zacher, A ^b   Nass, A ^c   Urban, R ^d   Werner, C ^e   Spevakne Gorocs T ^f   Kungel, M ^f   Ebrecht, M ^f   Modell, S ^f  

^a Medical Practice   (Germany)

^b Practice   (Germany)

^c Medical Practice   (Germany)

^d Medical Practice   (Germany)

^e Otsuka Pharma GmbH   (Germany)

^f BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; AKATHISIA; ARTICLE; ATAXIA; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GAIT DISORDER; HEART ARRHYTHMIA; HUMAN; HYPERKINESIA; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MENTAL HEALTH; MULTICENTER STUDY; MUSCLE SPASM; OUTPATIENT; PRIORITY JOURNAL; PSYCHIATRIST; PSYCHOSIS; RECURRENT DISEASE; SCHIZOPHRENIA; SCORING SYSTEM; SIDE EFFECT; SOCIAL PSYCHOLOGY; SOCIAL STATUS; SUICIDE ATTEMPT; TREATMENT OUTCOME; TREMOR; WELLBEING; GERMANY; HEALTH CARE FACILITY; HEALTH SURVEY; HOSPITALIZATION; POSTMARKETING SURVEILLANCE; PROSPECTIVE STUDY; PSYCHOLOGY; QUESTIONNAIRE;

ANTIPSYCHOTIC AGENTS; GERMANY; HEALTH STATUS INDICATORS; HUMANS; PHYSICIANS' OFFICES; PIPERAZINES; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; PSYCHOLOGY; QUESTIONNAIRES; QUINOLONES; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 68149138448     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0028-1112129     Document Type: Article

References (44)

1. Andreasen NC, Carpenter WT Jr, Kane JM et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005 ; 162 : 441-449
2. Beuzen J-N, Schirr K, Pans M et al Effectiveness of aripiprazole in a naturalistic setting: a european multicenter study. 13th Biennial Winter Workshop on Schizophrenia Research. Davos, Switzerland ; 2006
3. Bullinger M, Kirchberger I. Der SF-36 Fragebogen zum Gesundheitszustand. Handbuch f ü r die deutschsprachige Fragebogenversion. G ö ttingen: Hogrefe Verlag f ü r Psychologie ; 1998
4. Burris KD, Molski TF, Xu C et al. Aripiprazole, a novel antipsychotic drug, is a high affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002 ; 302 : 381-389
5. Dickinson D, Bellack AS, Gold JM. Social/communication skills, cognition, and vocational functioning in schizophrenia. Schizophr Bull 2007 ; 33 : 1213-1220
6. Eack SM, Newhill CE. Psychiatric Symptoms and quality of life in schizophrenia: a meta-analysis. Schizophr Bull 2007 ; 33 : 1 225-1237
7. Fan X, H enderson DC, C hiang E et a l. Sexual functioning, psychopathology and quality of life in patients with schizophrenia. Schizophr Res 2007 ; 94 : 119-127
8. Fleischhacker WW. Aripiprazole. Expert Opin Pharmacother 2005 ; 6 : 2091-2101
9. Fuchs J, Steinert T. Patients with a first episode of schizophrenia spectrum psychosis and their pathways to psychiatric hospital care in South Germany. Soc Psychiatry Psychiatr Epidemiol 2004 ; 39 : 375-380
10. Gr ü nder G, Kungel M, Ebrecht M et al. Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia. Pharmacopsychiatry 2006 ; 39 (Suppl. 1) : S21 - 25
11. Guy W. Clinical Global Impressions scale In: US Dept Health E, and Welfare publication (AMD) ed, ECDEU Assessment Manual for Psychopharmacology. Rockville: National Institute of Mental Health ; 1976 ; 221-227
12. Hanssen L, L ' Italien G, MacQuade R et al Evaluation of quality of life in community-treated schizophrenic patients: a naturalistic open-label study comparing aripiprazole to standard-of-care. (Schizophrenia Trial of Aripiprazole: Star Study). 14th European Congress of Psychiatry. Nice, France ; 2006
13. Hirose T, Uwahodo Y, Yamada S et al. Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-eff ect profile. J Psychopharmacol 2004 ; 18 : 375-383
14. Hofer A, Rettenbacher MA, Widschwendter CG et al. Correlates of subjective and functional outcomes in outpatient clinic attendees with schizophrenia and schizoaff ective disorder. Eur Arch Psychiatry Clin Neurosci 2006 ; 256 : 246-255
15. Jordan S, Koprivica V, Chen R et al. The antipsychotic aripiprazole is a potent, partial antagonist at the human 5-HT1A receptor. Eur J Pharmacol 2002 ; 441 : 137-140
16. Kane JM, Meltzer HY, Carson WH Jr et al. Aripiprazole for treatmentresistant schizophrenia: results of a multicenter, randomized, doubleblind, comparison study versus perphenazine. J Clin Psychiatry 2007 ; 68 : 213-223
17. Kerwin R, Millet B, Herman E et al. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients - Schizophrenia Trial of Aripiprazole: (STAR) study. Eur Psychiatry 2007 ; 22 : 433-443
18. Klein N, Wallner H, Kasper S. Aripiprazol - ein partieller Dopamin- Agonist als neues Antipsychotikum. Psychopharmakotherapie 2006 ; 13 : 49-54
19. Kompetenznetz Schizophrenie. Projektverbund II (PV II), Teilverbund 2: Optimierung der Langzeitbehandlung. http://www.kompetenznetzschizophrenie.de/ rdkns/653-14.htm Accessed 11.04.2008
20. Lambert M, Naber D. Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life. CNS Drugs 2004 ; 18 (Suppl. 2) : 5 - 17 ; discussion 41-43
21. Lambert M, Riedel M, M ö ller H-J et al. Das Antipsychotikum Aripiprazol Wirksamkeit und Vertr ä glichkeit. Psychiatrie 2004 ; 1 : 50-62
22. Lenroot R, Bustillo JR, Lauriello J et al. Integrated treatment of schizophrenia. Psychiatr Serv 2003 ; 54 : 1499-1507
23. Leucht S, Lasser R. The concepts of remission and recovery in schizophrenia. Pharmacopsychiatry 2006 ; 39 : 161-170
24. Liberman RP. Coping with chronic mental disorders: a framework for hope In: Liberman RP, ed. Psychiatric rehabilitation of chronic mental patients. Washington, DC: American Psychiatric Press ; 1988 ; 1-28
25. Liberman RP, Mueser KT, Wallace CJ et al. Training skills in the psychiatrically disabled: learning coping and competence. Schizophr Bull 1986 ; 12 : 631-647
26. Lieberman JA, Stroup TS, MacEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 ; 353 : 1209-1223
27. Marder SR, MacQuade RD, Stock E et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003 ; 61 : 123-136
28. MacEvoy JP, Lieberman JA, Stroup TS et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006 ; 163 : 600-610
29. Melle I, Friis S, Hauff E et al. Social functioning of patients with schizophrenia in high-income welfare societies. Psychiatr Serv 2000 ; 51 : 223-228
30. Messer T, Schmauss M, Spevakne-Goeroecs T et al. Clinical use of aripiprazole in patients with schizophrenia - a real-life setting. Results from the German Postmarketing Surveillance Study. W J Biol Pschiatry 2007 ; 1-8
31. Morrison RL, Bellack AS. Social functioning of schizophrenic patients: clinical and research issues. Schizophr Bull 1987 ; 13 : 715-725
32. Nuechterlein KH, Dawson ME. A heuristic vulnerability/stress model of schizophrenic episodes. Schizophr Bull 1984 ; 10 : 300-312
33. Sanderson K, Andrews G. Prevalence and severity of mental healthrelated disability and relationship to diagnosis. Psychiatr Serv 2002 ; 53 : 80-86
34. Stroup TS, Lieberman JA, MacEvoy JP et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006 ; 163 : 611-622
35. Swartz MS, Perkins DO, Stroup TS et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry 2007 ; 164 : 428-436
36. Tandon R, Marcus RN, Stock EG et al. A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaff ective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA). Schizophr Res 2006 ; 84 : 77-89
37. Tulloch AD, Fearon P, David AS. Social outcomes in schizophrenia: from description to action. Curr Opin Psychiatry 2006 ; 19 : 140-144
38. Os J van, Driessen G, Gunther N et al. Neighbourhood variation in incidence of schizophrenia. Evidence for person-environment interaction. Br J Psychiatry 2000 ; 176 : 243-248
39. Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996 ; 34 : 220-233
40. Ware JE, Kosinski M, Keller SD. How to Score the SF-12 Physical and Mental Health Summary Scales. Boston: The Health Institute, New England Medical Center ; 1998
41. West JC, Wilk JE, Olfson M et al. Patterns and quality of treatment for patients with schizophrenia in routine psychiatric practice. Psychiatr Serv 2005 ; 56 : 283-291
42. World Health Organisation. International statistical classification of diseases and related health problems, 10th revision. Geneva ; 2007
43. Yanos PT, Moos RH. Determinants of functioning and well-being among individuals with schizophrenia: an integrated model. Clin Psychol Rev 2007 ; 27 : 58-77
44. Zubin J, Spring B. Vulnerability - a new view of schizophrenia. J Abnorm Psychol 1977 ; 86 : 103-126